Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: Results from the Studies of Left Ventricular Dysfunction (SOLVD)

American Heart Journal

Volumn 138, Issue 5 I, 1999, Pages 849-855

  Knight, E L ^a   Glynn, R J ^a   McIntyre, K M ^a   Mogun, H ^a   Avorn, J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO;

ADULT; AGE; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DIURETIC THERAPY; DOUBLE BLIND PROCEDURE; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032716559     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70009-8     Document Type: Article

References (36)

1. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
2. Garg R, Yusef S, for the collaborative group on ACE inhibitor trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-6.
3. The CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
4. Kostis JB, Shelton BJ, Yusuf S, Weiss MB, et al. Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the Studies of Left Ventricular Dysfunction. Am Heart J 1994;128:358-64.
5. Kostis JB, Shelton B, Gosselin G, Goulet C. Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). Am Heart J 1996;131:350-5.
6. Devoy MAB, Tomson CRV, Edmunds ME, Feehally J, Walls J. Deterioration in renal function associated with angiotensin converting enzyme inhibitor therapy is not always reversible. J Int Med 1992; 232:493-8.
7. Moyses C, Higgins TJC. Safety of long-term use of lisinopril for congestive heart failure. Am J Cardiol 1992;70:91C-97C.
8. The large state peer review organization consortium. Heart failure treatment with angiotensin-converting enzyme inhibitors in hospitalized patients in 10 large states. Arch Intern Med 1997;157:1103-8.
9. Stafford RS, Saglam D, Blumenthal D. National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure. Arch Intern Med 1997;157:2460-4.
10. Houghton AR, Cowley AJ. Why are angiotensin converting enzyme inhibitors underutilized in the treatment of heart failure by general practitioners? Int J Card 1997;59:7-10.
11. Bridoux F, Hazzan M, Pallot JL, Fleury D, et al. Acute renal failure after the use of angiotensin converting enzyme inhibitors in patients without renal artery stenosis. Neph Dial Trans 1992;7:100-4.
12. Gottlieb SS, Robinson S, Weir MR, Fisher ML, Krichten C.M. Determinants of the renal response to ACE inhibition in patients with congestive heart failure [abstract]. Am Heart J 1992;124:131.
13. Packer M, Lee WH, Medina N, Yushak M, Kessler PD. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Int Med 1987;106:346-54.
14. Fliser D, Franek E, Joest M, Block S, et al. Renal function in the elderly: impact of hypertension and cardiac function. Kidney Int 1997;51:1196-204.
15. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
16. The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349:1787-92.
17. Bauer JH, Reams GP, Hewett J, et al. A randomized, double-blind, placebo-controlled trial to evaluate the effect of enalapril in patients with clinical diabetic nephropathy. Am J Kidney Dis 1992;20:443-57.
18. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 1996;156:286-9.
19. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Int Med 1997;127:337-45.
20. Packer M. Identification of risk factors predisposing to the development of functional renal insufficiency during treatment with converting-enzyme inhibitors in chronic heart failure. Cardiology 1989; 76(suppl 2):50-5.
21. Mandal AK, Markert RJ, Saklayen MG, Mankus RA, Yokokawa K. Diuretics potentiate angiotensin converting enzyme inhibitor-induced acute renal failure. Clin Nephrol 1994;42:170-4.
22. Dietz R, Nagel F, Osterziel K-J. Angiotensin-converting enzyme inhibitors and renal function in heart failure. Am J Cardiol 1992;70:119c-125c.
23. Mignat C, Unger T. ACE inhibitors: drug interactions of clinical significance. Drug Safety 1995;12:334-47.
24. van Essen GG, Apperloo AJ, Rensma PL, Stegeman CA, et al. Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline? Kidney Int Suppl 1997;63:S58-S62.
25. Elving LD, Wetzels JF, van Lier HJ, de Nobel E, Berden JH. Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Results of a 2-year prospective, randomized study. Diabetologia 1994;37:604-9.
26. Barone FC, Nelson AH, Ohlstein EH, Willette RN, et al. Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone rats. J Pharmacol Exp Ther 1996;279:948-55.
27. The SOLVD Investigators. Studies of left ventricular function (SOLVD): rationale, design and methods. Two trials that evaluate the effect of enalapril in patients with reduced ejection fraction. Am J Cardiol 1990;66:315-22.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1956;53:457-81.
29. Cox DR. Regression models and life-tables (with discussion). J Roy Statist Soc Series B 1972;34:187-220.
30. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet 1997;349:747-52.
31. Schwartz D, Kornowski R, Schwartz IF, Dotan I, Weinreb B, Averbuch M, et al. Prediction of renal impairment in elderly patients with congestive heart failure treated with captopril. Cardiovasc Drugs Ther 1996;10:75-9.
32. Malmrose LC, Gray SL, Pieper CF, Blazer DG, et al. Measured versus estimated creatinine clearance in a high-functionaing elderly sample: MacArthur Foundation study of successful aging. J Am Geriatr Soc 1993;41:715-21.
33. Macdowell P, Kalra PA, O'Donoghue DJ, Waldek S, et al. Risk of morbidity from renovascular disease in elderly patients with congestive cardiac failure. Lancet 1998;352:13-6.
34. Mandal AK, Markert RJ, Saklayen MG, Mankus RA, Yokokawa K. Diuretics potentiate angiotensin converting enzyme inhibitor-induced acute renal failure. Clin Nephrol 1994;42:170-4.
35. Toto RD. Renal insufficiency due to angiotensin-converting enzyme inhibitors. Miner Electrolyte Metab 1994;20:193-200.
36. Textor SC. Renal failure related to angiotensin-converting enzyme inhibitors. Semin Nephrol 1997;17:67-76.